Revolution Medicines, Inc. Common Stock (RVMD) Stock Analysis
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy28 analystsStrengths
- ✓Altman Z 30.8 — safe-zone balance sheet
Risks
- ⚠5 loss-making years in recent history
What's happening with RVMD
Price History
5-Year Weekly Candlestick Chart
Profile
Strong financial health; growth, profitability, earnings quality and valuation lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-2.4%)0/25
- P/S (3796.5x)0/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (-91.5%)0/25
- Net margin (-3768.3%)0/25
- Operating margin (-4207.1%)0/25
- Financial Health100/100 · Strong
- Altman Z (30.83)25/25
- Current ratio (6.80)25/25
- Interest coverage (no interest expense)25/25
- Net cash / debt (Net cash)25/25
- Quality0/100 · Weak
- Piotroski F (1/9)0/25
- Beneish M (n/a)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 647.4%)0/25
About Revolution Medicines, Inc. Common Stock
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. Show more
The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Headquarters: REDWOOD CITY, CA · Employees: 883 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellOption exercise · filed 2026-09-24-5070 sh2026-09-22
- SellOpen market sale · filed 2026-09-24-100 sh2026-09-22
- SellOpen market sale · filed 2026-09-24-1500 sh2026-09-22
- SellOpen market sale · filed 2026-09-24-2648 sh2026-09-22
- SellOpen market sale · filed 2026-09-24-4985 sh2026-09-22
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-2.4%D
Grade D: NegativeTTM FCF / Market Cap — vs own 5Y history: -15.8%–-2.3% · highest in history
P/S (TTM)3796.45xD
Grade D: ExpensivePrice / TTM Revenue (own statements)
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales3815.5xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio29.58xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-0.24A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-91.5%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-39.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-3768.3%D
Grade D: LowNet Income / Revenue
Operating Margin—
TTM EBIT / TTM Revenue
Gross Margin—
Gross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
100A+Altman Z-Score30.83A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio6.80xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio6.97xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage—
EBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.16xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Quality
5/5 Loss Years0EPiotroski F-Score1/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability647.4%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.01xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$10.28
Cash & short-term investments per share (Finnhub)
Book Value / Share$8.28
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$1.91B
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$1.50B
Shareholders' equity (book value)
Asset / Liability2.99xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$44.37B
Current Market Capitalization
Beta1.44C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Company is effectively debt-free after netting cash.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 26, 2026
Key Insights: Revolution Medicines, Inc. Common Stock (RVMD)
Revolution Medicines, Inc. Common Stock meets only 1 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 30.83 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Company is effectively debt-free after netting cash.
- Revolution Medicines, Inc. Common Stock posted a net loss in 5 of 5 available completed fiscal years (2020–2025).
- At a valuation score of 20/100, RVMD trades at a premium to its historical multiples.
See how RVMD ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all RVMD moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 24 | Regular | 200.88 | +5.32% | 2.84 |
| Sep 24 | After-hours | 198.51 | +4.07% | 2.26 |
Frequently Asked Questions about RVMD
Is RVMD stock a buy right now?
PreMarketPrice's quantitative model rates Revolution Medicines, Inc. Common Stock's financial health at 100/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is RVMD stock overvalued?
Revolution Medicines, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Revolution Medicines, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for RVMD. The Earnings section lists recent reports and updates as dates are announced.
What sector does Revolution Medicines, Inc. Common Stock operate in?
Revolution Medicines, Inc. Common Stock operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Revolution Medicines, Inc. Common Stock do?
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers.
About Revolution Medicines, Inc. Common Stock (RVMD) Stock
Revolution Medicines, Inc. Common Stock (RVMD) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. Real-time pricing data for Revolution Medicines, Inc. Common Stock is available on this page with a market capitalization of $44.4 billion. The financial health score for RVMD is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for RVMD stock.
RVMD Stock Analysis & Key Metrics
On PreMarketPrice, you can track Revolution Medicines, Inc. Common Stock (RVMD) across multiple dimensions:
- Pre-market price & movement: Real-time RVMD stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for RVMD with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Revolution Medicines, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for RVMD.
- Sector peers: Compare RVMD against 10 other healthcare stocks on key financial metrics.
Is RVMD a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Revolution Medicines, Inc. Common Stock (RVMD) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Revolution Medicines, Inc. Common Stock (RVMD) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.